404 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Acquired by HTG Investment Advisors Inc.

HTG Investment Advisors Inc. purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 404 shares of the company’s stock, valued at approximately $204,000.

Several other hedge funds and other institutional investors have also modified their holdings of IDXX. Empowered Funds LLC boosted its position in shares of IDEXX Laboratories by 28.0% during the first quarter. Empowered Funds LLC now owns 1,039 shares of the company’s stock worth $561,000 after buying an additional 227 shares during the period. Atomi Financial Group Inc. boosted its position in shares of IDEXX Laboratories by 3.4% during the first quarter. Atomi Financial Group Inc. now owns 637 shares of the company’s stock worth $344,000 after buying an additional 21 shares during the period. Concurrent Investment Advisors LLC boosted its position in shares of IDEXX Laboratories by 12.1% during the first quarter. Concurrent Investment Advisors LLC now owns 446 shares of the company’s stock worth $241,000 after buying an additional 48 shares during the period. Choate Investment Advisors boosted its position in shares of IDEXX Laboratories by 4.2% during the first quarter. Choate Investment Advisors now owns 2,042 shares of the company’s stock worth $1,103,000 after buying an additional 82 shares during the period. Finally, NorthRock Partners LLC boosted its holdings in IDEXX Laboratories by 14.6% in the first quarter. NorthRock Partners LLC now owns 527 shares of the company’s stock valued at $285,000 after purchasing an additional 67 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Up 0.1 %

IDEXX Laboratories stock opened at $433.28 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $404.74 and a 1-year high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The stock has a market cap of $35.48 billion, a PE ratio of 41.78, a P/E/G ratio of 3.70 and a beta of 1.36. The stock’s fifty day moving average is $472.83 and its two-hundred day moving average is $485.19.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. During the same period last year, the firm earned $2.53 earnings per share. IDEXX Laboratories’s quarterly revenue was up 6.6% on a year-over-year basis. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. decreased their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. BTIG Research assumed coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price for the company. Barclays decreased their target price on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Piper Sandler reiterated a “neutral” rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, Stifel Nicolaus decreased their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $552.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.